Better Therapeutics (Better Therapeutics) Cash Conversion Cycle : 0.00 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Better Therapeutics Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Better Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2023 was 0.
Better Therapeutics's Days Inventory for the three months ended in Sep. 2023 was 0.
Better Therapeutics's Days Payable for the three months ended in Sep. 2023 was 0.
Therefore, Better Therapeutics's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2023 was 0.00.

Better Therapeutics Cash Conversion Cycle Historical Data

The historical data trend for Better Therapeutics's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Better Therapeutics Cash Conversion Cycle Chart

Better Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash Conversion Cycle

-136.16

-227.19

Better Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash Conversion Cycle	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Better Therapeutics's Cash Conversion Cycle

For the Biotechnology subindustry, Better Therapeutics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Better Therapeutics's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Better Therapeutics's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Better Therapeutics's Cash Conversion Cycle falls into.

Better Therapeutics Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Better Therapeutics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+	0	-	0
	=	0.00

Better Therapeutics's Cash Conversion Cycle for the quarter that ended in Sep. 2023 is calculated as:

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+	0	-	0
	=	0.00

Better Therapeutics (OTCPK:BTTX) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Better Therapeutics Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Better Therapeutics's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Better Therapeutics (Better Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » Cash Conversion Cycle

Comparable Companies

Traded in Other Exchanges

N/A

Address

548 Market Street, Suite 49404, San Francisco, CA, USA, 94104

Website

https://www.bettertx.com

Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.

Executives

Elder Granger	director	5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Mark A. Berman	officer: Chief Medical Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Frank Karbe	director, officer: See Remarks	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David P Perry	director, 10 percent owner, officer: See Remarks	1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Andrew J. Armanino	director	C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
Georgianna Maule-ffinch 2015 Trust	10 percent owner	C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark Heinen	officer: See Remarks	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Risa J Lavizzo-mourey	director	GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Kevin J Appelbaum	director, 10 percent owner, officer: Chief Executive Officer	4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Suying Liu	director	311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Justin Zamirowski	officer: Chief Commercial Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds	officer: Chief Product Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Richard H Carmona	director	1221 BROADWAY, OAKLAND CA 94612
David P. Perry 2015 Trust	10 percent owner	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104